pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·4h ago·1 min read
save

Centene reports strong enrollment growth but modest scale for its ICHRA offering

Aug 6, 2026·read at Endpoints ↗EarningsPositive

Centene's chief executive Sarah London said the company's individual coverage health reimbursement arrangement (ICHRA) business is experiencing a strong enrollment growth rate, though the total number of participants remains modest.

ICHRA plans let employers reimburse employees for individual health insurance premiums, offering a flexible alternative to traditional group coverage.

The comments were made during Centene's recent earnings call, highlighting the insurer's focus on expanding this newer product line despite its still‑small scale.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Fixing the mess under ICHRA’s hood”

read at Endpoints ↗
79 words · retrieved 4h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 9m agoJudge signs off on Teva's $35M settlement over delayed inhaler genericsEndpoints
  • 3h agoIntellia identifies genetic risk factor for liver complications in CRISPR trialEndpoints
  • 5h agoSarepta pushes back Elevidys timeline; Emergent lays off 90 staffersEndpoints
  • 6h agoTarsus bets $450M on Alkeus’ Stargardt drugEndpoints
  • 7h agoMerck KGaA readies tariff refunds worth €40M for life science customersEndpoints